Methods used by WHO to estimate the global burden of TB ...

Methods used by WHO to estimate the global

burden of TB disease

17 October 2019

Glaziou P1 Dodd PJ2 Dean A1 Floyd K1

1 Global TB Programme World Health Organization Geneva Switzerland

2 School of Health and Related Research University of Sheffield UK

Abstract

This paper describes methodological details used by WHO in 2019 to estimate TB incidence and

mortality Incidence and mortality are disaggregated by HIV status age and sex Methods to derive

MDR-TB burden indicators are detailed Four main methods are used to derive incidence (i) results

from TB prevalence surveys (24 countries 60 of global incidence) (ii) notifications in high-income

countries adjusted by a standard factor to account for under-reporting and underdiagnosis (142

countries 6 of global incidence) and (iii) national inventory studies (7 countries 18 of global

incidence) (iv) case notification data combined with expert opinion about case detection gaps (43

countries representing 16 of global incidence in 2018) Mortality was obtained from national vital

registration systems of mortality surveys in 123 countries (55 of global HIV-negative TB

mortality) and among 20 of them based on estimates published by the Institute of Health Metrics

and Evaluation In other countries mortality was derived indirectly from incidence and case fatality

ratio

1

1 Introduction Estimates of the burden of disease caused by TB and measured in terms of incidence prevalence

and mortality are produced annually by WHO using information gathered through surveillance

systems (case notifications and death registrations) special studies (including surveys of the

prevalence of disease) mortality surveys ldquoinventory studiesrdquo of under-reporting of detected TB

in-depth analysis of surveillance and other data expert opinion and consultations with countries In

June 2006 the WHO Task Force on TB Impact Measurement was established1 with the aim of

ensuring that WHOrsquos assessment of whether global targets were achieved should be as rigorous

robust and consensus-based as possible The Task Force reviewed methods and provided

recommendations in 2008 2009 2015 2016 and most recently in April 2018

2 Historical background Historically a major source of data to derive incidence estimates were results from tuberculin

surveys conducted in children2 Early studies showed the following relationship between the annual

risk of infection denoted λ and the incidence of smear positive TB denoted Is+ one smear positive

case infects on average 10 individuals per year for a period of 2 years and a risk of infection of 10-2y-1

corresponds approximately to an incidence rate of 50 10-5y-1 However this relationship no longer times

holds in the context of modern TB control and in HIV settings3 In addition to uncertainty about

the relationship between λ and Is+ estimates of incidence obtained from tuberculin surveys suffer

from other sources of uncertainty and bias including unpredictable diagnostic performance of the

tuberculin test4 digit preference when reading and recording the size of tuberculin reactions5

sensitivity to assumptions about reaction sizes attributed to infection6 sensitivity to the common

assumption that the annual risk of infection is age invariant and lastly sensitivity of overall TB

incidence estimates to the assumed proportion of TB incidence that is smear positive

A first global and systematic estimation exercise led by WHO in the early 1990s estimated that there

were approximately 8 million incident TB cases in 1990 (152 10-5y-1) and 26-29 million deaths times

(46-55 10-5y-1)7 A second major reassessment was published in 19998 with an estimated 8 milliontimes

incident cases for the year 1997 (136 10-5y-1) and 19 million TB deaths (32 10-5y-1) The most times times

2

important sources of information were case notification data for which gaps in detection and

reporting were obtained from expert opinion In addition data from 24 tuberculin surveys were

translated into incidence and 14 prevalence surveys of TB disease were used

3 Incidence

TB incidence has never been measured through population based surveys at national level because

this would require long-term studies among large cohorts of people (hundreds of thousands)

involving high costs and challenging logistics Notifications of TB cases provide a good proxy

indication of TB incidence in countries that have both high-performance surveillance systems (for

example there is little under-reporting of diagnosed cases) and where the quality of and access to

health care means that few cases remain undiagnosed and overdiagnosis is limited In the large

number of countries where these criteria are not yet met better estimates of TB incidence can be

obtained from an inventory study An inventory study aims at quantifying the level of

under-reporting of detected TB cases if certain conditions are met capture-recapture methods can

also be used to estimate TB incidence 9

The ultimate goal of TB surveillance is to directly measure TB incidence from national case

notifications in all countries This requires a combination of strengthened surveillance better

quantification of under-reporting and over-reporting (ie the number of newly diagnosed cases that

are missed by surveillance systems and the number of cases over-diagnosed with TB) and universal

access to quality health care (to minimize under-diagnosis of cases and overdiagnosis) A TB

surveillance checklist developed by the WHO Global Task Force on TB Impact Measurement

defines the standards that need to be met for notification data to provide a direct measure of TB

incidence10

Methods currently used by WHO to estimate TB incidence can be grouped into four major

categories Figure 1 shows the distribution of countries according to the four categories - in reality

methods are often combined to estimate entire time series and the shown distribution of countries

reflects the dominant method used to estimate incidence over the most recent years

3

1 Results from TB prevalence surveys Incidence is estimated using prevalence survey results

and estimates of the distribution characteristics of duration of disease accounting for the impact

of HIV coinfection and ART This method is used for 24 countries of which 23 have national

survey data and one ndash India ndash has a survey in one state The 24 countries accounted for 60 of

the estimated global number of incident cases in 2018

2 Notifications in high-income countries adjusted by a standard factor to account for

under-reporting under-diagnosis and over-diagnosisover-reporting This method is used

for 142 countries that comprise all high-income countries except the Netherlands and the United

Kingdom plus selected upper-middle income countries with low levels of underreporting

including Brazil China and the Russian Federation For three countries (France Republic of

Korea and Turkey) the adjustment was country specific based on results from reports of

underreporting These 142 countries accounted for 6 of the estimated global number of

incident cases in 2018

3 Results from inventorycapture-recapture studies This method is used for 7 countries

China Egypt Indonesia Iraq the Netherlands the United Kingdom and Yemen They

accounted for 18 of the estimated global number of incident cases in 2018

4 Case notification data combined with expert opinion about case detection gaps Expert

opinion elicited in regional workshops or country missions is used to estimate levels of

under-reporting and under-diagnosis Trends are estimated using either mortality data surveys of

the annual risk of infection or exponential interpolation using estimates of case detection gaps

for three years This method is considered generally unreliable and used when other methods are

not applicable due to missing or poor quality data In this report this method is used for 43

countries that accounted for 16 of the estimated global number of incident cases in 2018

The code implementing the different estimation methods is available at the following public

repository httpsgithubcomglaziougtb2019

Four main methods Method 1 - Case notification data combined with expert opinion about case detection gaps

Expert opinion elicited in regional workshops national consensus workshops or country missions

is used to estimate levels of under-reporting over-reporting (false positive diagnoses that may occur

4

particularly in the context of systematic screening in populations with relatively low probability of

TB disease) and under-diagnosis Trends are estimated using either mortality data national repeat

surveys of the annual risk of infection or exponential interpolation using estimates of case detection

gaps for specific years The estimation of case detection gaps is essentially based on an in-depth

analysis of surveillance data experts provide their educated best guess about the range of the

plausible detection gap g and incidence I is obtained from

where N denotes case notifications f denotes a cubic spline function in countries with large

year-to-year fluctuations in N or else the identity function The incidence series are completed

using assumptions about changes in CFR over time in countries with evidence of improvements in

TB prevention and care such as increased detection coverage over time or improved treatment

outcomes ensuring that the following inequality holds

where M denotes mortality

A full description of the methods used in regional workshops where expert opinion was

systematically elicited following an in-depth analysis of surveillance data is publicly available in a

report of the workshop held for countries in the African Region (in Harare Zimbabwe December

2010)11 In some countries case reporting coverage changed significantly during the period

2000-2018 as a result of disease surveillance reforms (eg disease surveillance was thoroughly

reformed after the SARS epidemic in China the Ministry of Justice sector notified cases among

prisoners in Russia starting in the early 2000s) Trends in incidence are derived from repeat

tuberculin survey results in Bhutan India and Yemen and from trends in mortality or case

notifications

Case proportions are assumed to follow a Beta distribution with parameters α and β obtained from

the expected value E and variance V using the method of moments12 as follows

5

(1)

Time series are built according to the characteristics of the levels of under-reporting and

under-diagnosis that were estimated for specific reference years (three reference years in regional

workshops conducted around 2010) A cubic spline extrapolation of V and E with knots set at the

reference years is used for countries with low-level or concentrated HIV epidemics In countries

with a generalized HIV epidemic the trajectory of incidence is based on the annual rate of change in

HIV prevalence and time changes in the fraction F of incidence attributed to HIV determined as

follows

where h is the prevalence of HIV in the general population ρ is the TB incidence rate ratio among

HIV-positive individuals over HIV-negative individuals and ϑ is the prevalence of HIV among new

TB cases

If there are insufficient data to determine the factors leading to time-changes in case notifications

incidence are assumed to follow a horizontal trend going through the most recent estimate of

incidence

Limitations of the method based on eliciting expert opinion about gaps in case detection and

reporting include a generally small number of interviewed experts lack of clarity about vested

interests when eliciting expert opinion lack of recognition of over-reporting (due to over-diagnosis

eg in some countries implementing a large-scale systematic population screening policy that may

result in many people with abnormal chest X-ray but no bacteriological confirmation of TB disease

being notified and treated as new TB cases) or in countries where cases with confirmed non-TB

mycobacteria were not systematically reviewed and those judged non-TB were not de-notified

6

incomplete data on laboratory quality and high proportion of patients with no bacteriological

confirmation of diagnosis are a potential source of error in estimates

Method 2 - Results from TB prevalence surveys

Two approaches were used to derive incidence from prevalence

In a first approach incidence is estimated using measurements from national surveys of the

prevalence of TB disease combined with estimates of the duration of disease Incidence is estimated

as the prevalence of TB divided by the average duration of disease assuming epidemic equilibrium

let N denote the size of a closed population with the number of birth and deaths the same for a

period Δtgt0 let C be the number of prevalent TB cases P the prevalence rate so that P=CN Let m

denote the rate of exit from the pool of prevalent cases through mortality spontaneous self-cure or

cure from treatment and I the rate at which new cases are added to the pool At equilibrium during

the time period Δt and further assuming exponentially distributed durations d such that d=m-1

(3)

In practice the average duration of presence in the pool of prevalent cases cannot be directly

measured For example measurements of the duration of symptoms in prevalent TB cases that are

detected during a prevalence survey are systematically biased towards lower values since survey

investigations truncate the natural history of undiagnosed disease Measurements of the duration of

disease in notified cases ignore the duration of disease among non-notified cases and are affected by

recall biases

Literature reviews have provided estimates of duration of disease in untreated TB cases from the

pre-chemotherapy era (before the 1950s) The best estimate of the mean duration of untreated

disease (for smear-positive cases and smear-negative cases combined) in HIV-negative individuals is

about three years There are few data on the duration of disease in HIV-positive individuals The

assumed distributions of disease durations are shown in Table 1

7

A second approach consists of estimating disease duration using three compartments susceptibles

(S) untreated for TB (U) and treated for TB (T) The size of U and T is obtained from the results of

the prevalence survey Transition rates from U to T are determined as follows

Where I denotes Incidence μ and θ denote mortality and self-cure (remission) or cure (with

subscripts u and t indicating untreated and treated cases) respectively δ denotes the rate of removal

from U through detection and treatment At equilibrium the above two equations simplify to

Disease duration (untreated) is obtained from

where

is the proportion of incidence that dies or self-cures before treatment π is assumed distributed

uniform with bounds 0 and 01 Table 2 shows estimates of incidence from four recent prevalence

surveys using this method

Limitations of this method include the insufficient power of disease prevalence surveys to estimate

the number of prevalent TB cases on treatment with sufficient precision Further in most surveys

cases found on treatment during the survey do not have a bacteriological status at onset of treatment

8

documented based on the same criteria as survey cases (particularly when culture or Xpert were not

performed routinely) The method however provides more robust estimates of incidence compared

with those obtained from expert opinion (method 1)

In countries with high-level HIV epidemics that completed a prevalence survey the prevalence of

HIV among prevalent TB cases was found systematically lower than the prevalence of HIV among

newly notified TB cases with an HIV prevalence rate ratio among prevalent TB over notified cases

ranging from 007 in Rwanda (2012) to 05 in Malawi (2013) The HIV rate ratio was pooled using

random-effects model fitting data from countries with data collected over the period 2012-2018

including Kenya Malawi Rwanda Tanzania Uganda Zambia and Zimbabwe using the R package

metafor13 (Figure 2) The pooled ratio value is used to predict HIV prevalence in prevalent cases

from HIV prevalence in notified cases in African countries that were not able to measure the

prevalence of HIV among survey cases

The above two methods to derive incidence from prevalence are compared in Table 3 It is not clear

a priori which method will perform better The second method requires a sufficient number of cases

on treatment at the time of the survey (as a rule of thumb at least 30 cases) to generate relatively

stable estimates When both methods can be applied (so far only in selected low-HIV settings)

results from two methods may be combined in a statistical ensemble approach as follows

The incidence rate obtained using method i is assumed distributed Beta with shape and scale

parameters αi+1 and β i+1 respectively and determined using the method of moments based on

equation 3 IisimB (α i+1β i+1) so that

The combined probability is then expressed as

(4)

9

Indirect estimation of incidence from prevalence relies on a number of assumptions difficult to

verify including (i) epidemic in a stable state of equilibrium (ii) correctly assumed distribution of

disease duration for each case category (iii) size of the unmeasured prevalence of clinically

diagnosed TB and childhood TB correctly estimated

Method 3 - Notifications in high-income countries adjusted by a standard factor to account for

under-reporting and under-diagnosis

TB surveillance systems from countries in the high-income group and other selected countries in the

upper-middle income group are assumed to perform similarly well on average in terms of

under-diagnosis and under-reporting Exceptions include the Republic of Korea where the

under-reporting of TB cases has recently been measured using annual inventory studies and France

where the estimated level of under-reporting was communicated by public health authorities based

on unpublished survey results In the United Kingdom and the Netherlands incidence was obtained

using capture-recapture modeling (see next section) Surveillance data in this group of countries are

usually internally consistent Consistency checks include detection of rapid fluctuations in

notification rates and in the ratio of TB deaths TB notifications (MN ratio) which may be

indicative of reporting problems

Method 4 - Inventory studies capture-recapture modelling

This method was used for 7 countries China Egypt14 Indonesia Iraq15 the Netherlands16 the

United Kingdom17 and Yemen18 Capture-recapture modelling is considered in studies with at least 3

sources (lists) and estimation of between source dependences9 The surveillance gap (proportion of

unreported incident cases) in the UK and the Netherlands was assumed time invariant In Yemen

trends in incidence were derived from results of two consecutive tuberculin surveys19 In Egypt

Indonesia and Iraq trends were derived using methods described in section describing method 1

Capture recapture modelling for estimating TB incidence requires the following six assumptions (i)

all cases should be observable (preclinical stages are rarely detected before they become

symptomatic) (ii) low proportion of mismatches and matching failures which typically requires a

large sampling fraction (iii) closed population during the study period (typically 3-6 months) (iv)

10

dependences between S data sources (S ge 3) accounted for in the model design but S-way

interaction assumed null - referrals between sources (eg clinic to lab) may imply an S-way

interaction invalidating the approach (of note in many high-burden countries there will not be 3

sources meeting requirements) (v) homogeneity of within-source observation probabilities across

subpopulation groups such as defined by socio demographic characteristics (vi) consistent case

definitions across sources It is anticipated that capture recapture may only be successfully

implemented in very few high-burden countries planning an inventory study

HIV-positive TB incidence Provider-initiated testing and counselling with at least 50 HIV testing coverage is the most widely

available source of information on the prevalence of HIV in TB patients However this source of

data is affected by selection biases particularly when coverage is closer to 50 than to 100 As

coverage of HIV testing continues to increase globally biases will decrease Other sources of

information on the prevalence of HIV among new TB cases include sero-surveys of a random

sample of newly diagnosed TB cases and HIV sentinel surveillance systems when they include TB as

a sentinel group The different data sources were combined using local polynomial regression fitting

by weighted least squares using weight values of 1 for data from a nationally representative survey

02 for data based on HIV sentinel surveillance and a value equal to testing coverage in the case of

data from provider-initiated HIV testing with coverage greater than 50 and zero weights when

testing coverage was less than 50 In countries with no surveillance data on HIV among TB cases

the prevalence of HIV was derived indirectly from the prevalence of HIV in the general population

based on the relationship between the prevalence of HIV in TB and the prevalence of HIV in the

general population shown in Annex 2 The TB incidence rate ratio (HIV-positiveHIV-negative)

was 19 (17 ndash 22) in 2015

Disaggregation by age and sex Estimates for men (males aged ge15 years) women (females aged ge15 years) and children (aged lt15

years) are derived as follows Age and sex disaggregation of smear-positive tuberculosis case

11

notifications has been requested from countries since the establishment of the data collection system

in 1995 but with few countries actually reporting these data to WHO In 2006 the data collection

system was revised to additionally monitor age disaggregated notifications for smear-negative and

extrapulmonary tuberculosis The revision also included a further disaggregation of the 0ndash14 age

group category to differentiate the very young (0ndash4) from the older children (5ndash14) While reporting

of age disaggregated data was limited in the early years of the data collection system reporting

coverage kept improving For 2012 case notifications age-specific data reached 99 83 and 83

of total smear-positive smear-negative and extrapulmonary tuberculosis global case notifications

Finally in 2013 another revision of the recording and reporting system was necessary to allow for

the capture of cases diagnosed using WHO-approved rapid diagnostic tests (such as Xpert

MTBRIF)20 This current revision requests the reporting of all new and relapse case notifications by

age and sex

While there are some nationwide surveys that have quantified the amount of under-reporting of

cases diagnosed in the health sector outside the network of the NTPs141621 none have produced

precise results by age Small-scale convenient-sampled studies indicate that under-reporting of

childhood tuberculosis can be very high2223 but extrapolation to national and global levels is not yet

possible Plans for implementation of nationwide surveys are under way in selected countries to

measure under-reporting of tuberculosis in children24 However producing estimates of TB

incidence among children remains challenging primarily due to the lack of well performing

diagnostics to confirm childhood TB and the lack of age-specific nationwide robust survey and

surveillance data

In order to maintain consistency with the total TB incidence and its uncertainty the approach to

estimating TB incidence by age and sex sought to disaggregate the total incidence into the incidence

in each age group and sex For countries where incidence was based on either a capture-recapture

study or a standard factor adjustment of notification and the implied case detection ratio was over

85 we disaggregated total tuberculosis incidence by age and sex in proportion to the notifications

For these countries surveillance systems were assumed to function well enough to inform patterns

by age and sex directly We also disaggregated incidence proportionally to notifications in countries

12

where fewer than 1000 TB cases were reported in total In these countries the stochasticity is strong

and modelled estimates less appropriate

For other countries one million samples were from a country lsquopriorrsquo for the proportion of incidence

in each age and sex group and the mean over samples where the implied incidence in every category

exceeded the corresponding notifications was used Where no samples had this property the 100

samples with the smallest undershoot were used

The prior for each country was based for adults on a hierarchical analysis for prevalence risk ratios

was developed based on prevalence survey data and Horton et alrsquos systematic review of prevalence

sex ratios25 This prior closely followed age and sex patterns for prevalence in countries with surveys

and made predictions (with greater uncertainty) for countries without prevalence surveys informing

the age patterns with prevalence surveys in the same WHO region and sex ratios from Hortonrsquos

WHO region specific meta-analysis The prior for children was based on based on a mathematical

modelling approach that simulates the course of natural history of TB in children starting from

estimates of tuberculous infection in children as a function of demographic and adult TB prevalence

and subsequently modelling progression to pulmonary and extra-pulmonary tuberculosis disease

taking into account country-level BCG vaccination coverage and HIV prevalence26 The

disaggregation by sex in children was based on a random-effects meta-analysis of the sex ratio in

notification data for children (0-14 years)

Finally for a small number of countries the approach above generated results lacked face validity

and a standard factor adjustment of notifications was used instead

Incidence of TB due to mycobacterium bovis

Mycobacterium bovis is the causal agent of bovine TB in cattle and zoonotic TB in people Bovine TB

has a major impact on livestock productivity and the livelihoods of poor and marginalised

communities The most common route of transmission to people is through the consumption of

13

unpasteurised dairy products Incidence of zoonotic TB is calculated by applying TB incidence

estimates from 2015 to the regional proportions of all TB cases that are estimated to be caused by

M bovis (1) A standard deviation of 50 relative to the best estimate of each regional proportion

was assumed when propagating uncertainty Due to an absence of routine reporting in most

countries where bovine TB is endemic these proportions were drawn from scientific studies 2728 that

lack regional representativeness As a result estimates have a large uncertainty range Mortality

(excluding TB deaths in HIV-infected individuals) was similarly calculated based on the same

proportions but this time applied to aggregated estimates of TB mortality by WHO region reduced

by a 20 factor to account for a higher proportion of extra-pulmonary TB with lower case fatality

There is a need to strengthen surveillance of zoonotic TB in order to understand the true burden of

disease One of the major barriers for diagnosis is that the most commonly used laboratory

procedures do not differentiate the M tuberculosis complex into the species of M bovis and M

tuberculosis Zoonotic TB also presents a treatment challenge It more often occurs in

extra-pulmonary sites and is inherently resistant to pyrazinamide one of the drugs of the standard

first-line anti-TB treatment regimen In the context of WHOrsquos End TB strategy 2016-2035 which

calls for diagnosis and treatment of every TB case zoonotic TB must be addressed This requires a

One Health approach linking human and animal health sectors to reduce the risk of transmission at

the human-animal interface

4 Drug resistance Following a revision of policy recommendations for the treatment of drug-resistant TB issued by

WHO in May 201629 all people with TB resistant to rifampicin with or without resistance to other

drugs should be treated with an MDR-TB regimen This includes patients with MDR-TB as well as

any other patient with TB resistant to rifampicin For this reason all global regional and country

level estimates of incidence and mortality of drug-resistant TB published in this report refer to cases

of TB resistant to rifampicin with or without additional resistance to other drugs (MDRRR-TB)

14

Global and regional estimates of the proportion of new and retreatment cases of TB that had

MDRRR-TB in 2018 were calculated using country-level information If countries had reported

data on the proportion of new and retreatment cases of TB that have MDRRR-TB from routine

surveillance or a survey of drug resistance the latest available information was used For data from

routine surveillance to be considered representative for new patients at least 80 of notified new

pulmonary laboratory-confirmed TB cases must have a documented DST result for at least

rifampicin For data from routine surveillance to be considered representative for retreatment

patients at least 80 of notified retreatment pulmonary laboratory-confirmed TB cases must have a

documented DST result for at least rifampicin

For countries that had not reported such data estimates of the proportion of new and retreatment

cases of TB that had MDRRR-TB were produced using modelling (multiple imputation by chained

equations) based on data from countries for which data do exist For each country estimates were

based on data from countries that were considered to be similar in terms of TB epidemiology The

observed and imputed estimates of the proportion of new and retreatment cases of TB that had

MDRRR-TB were then pooled to give a global estimate with countries weighted according to their

share of global notifications of new and retreatment cases

MDRRR-TB incidence

The following approach is considered based the proportions of new (pn) and retreated (pr) patients

with MDRRR-TB

1 Estimate the proportion r of relapses out of the sum of new and relapse cases

2 Estimate f the cumulative risk for incident cases to receive a non-relapse retreatment

(retreatment following previous treatment failure or return after default)

3 Approximate RR incidence as

15

where I is total TB incidence and is the risk of MDRRR-TB in relapses relative to

previously untreated cases

f may be estimated based on reported counts of cases disaggregated by treatment history over the

most recent years

MDRRR TB mortality

The VR mortality data reported to WHO by Member States does not differentiate between

MDR-TB and non-MDR-TB as a cause of death (there is no specific ICD-9 or ICD-10 codes for

MDR-TB although countries such as South Africa have allocated two specific codes U51 and U52

to classify deaths from MDR-TB and XDR-TB respectively)30 Therefore a systematic review and

meta-analysis of the published literature was undertaken to estimate the relative risk of dying from

MDR-TB compared with non MDR-TB We are assuming this relative risk of death is the same as

that for MDRRR-TB The global estimate of MDRRR-TB deaths is based on the following

formula

Where

m = global MDRRR-TB mortality

M = global TB mortality

p = overall proportion of MDRRR-TB among prevalent TB cases approximated by the weighted

average of the proportion of new and retreated cases that have MDRRR-TB

r = the relative risk of dying from MDRRR-TB versus non-MDRRR-TB

Resistance to isoniazid For countries where representative data are available for RR-TB among new and previously treated

cases the average proportion of isoniazid resistance without concurrent rifampicin resistance

(isoniazid monoresistance) is calculated by taking the ratio of identified isoniazid monoresistance

16

cases among tested new and retreatment cases Errors are assumed binomial The proportions of

resistance are then pooled using notifications of new and retreatment cases as weights to generate a

global estimate

Resistance to fluoroquinolones and XDR-TB For data from routine surveillance to be considered representative for second-line drug resistance

among RR-TB patients at least 80 of RR-TB cases must have a documented DST result for

second-line drugs The average proportion of MDR-TB cases with XDR-TB is calculated by taking

the ratio of identified XDR-TB cases among tested MDR-TB cases Errors are assumed binomial

The proportions of XDR-TB are then pooled using country-specific estimates of RR-TB incidence

as weights to generate a global estimate The same approach is followed to estimate the proportion

of RR-TB cases with resistance to fluoroquinolones

5 Prevalence from population-based surveys The best way to measure the prevalence of TB is through national population-based surveys of TB

disease3132 Measurements of prevalence are typically confined to the adult population exclude

extrapulmonary cases and do not allow the diagnosis of cases of culture-negative pulmonary TB

TB prevalence all forms and all ages (P) is measured as bacteriologically-confirmed pulmonary TB

prevalence (Pp) among those aged ge15 measured from national survey (Pa) adjusted for pulmonary

TB in children (Pc) and the proportion e of extra-pulmonary TB all ages

where c is the proportion of children among the total country population

17

The estimate of overall prevalence P is affected by sampling uncertainty (relative precision is

typically about 20) and uncertainty about e (of note values for e vary widely among countries with

high-performance TB surveillance) and Pc The quality of routine surveillance data to inform levels

of pulmonary TB in children and extra-pulmonary TB for all ages is often questionable

6 Mortality The best sources of data about deaths from TB (excluding TB deaths among HIV-positive people)

are vital registration (VR) systems in which causes of death are coded according to ICD-10

(although the older ICD-9 and ICD-8 classification are still in use in several countries) using

ICD-10 A15-A19 and B90 codes equivalent to ICD-9 010-018 and 137 When people with AIDS

die from TB HIV is registered as the underlying cause of death and TB is recorded as a contributory

cause Since one third of countries with VR systems report to WHO only the underlying causes of

death and not contributory causes VR data usually cannot be used to estimate the number of TB

deaths in HIV-positive people Two methods were used to estimate TB mortality among

HIV-negative people

direct measurements of mortality from VR systems or mortality surveys (see Figure 3) indirect estimates derived from multiplying estimates of TB incidence by estimates of the

CFR

Estimating TB mortality among HIV-negative people from vital registration data

and mortality surveys

As of July 2019 mortality data from 123 countries were used representing 55 of the estimated

number of TB deaths (among HIV-negative TB) globally in 2018

Estimates for 20 countries (Figure 3) including India and for South Africa (adjusted for HIVTB

miscoding) were obtained from the Institute of Health Metrics and Evaluation at

httpghdxhealthdataorggbd-results-tool readjusted to fit WHO mortality envelopes (the

estimated number of deaths in total) by using a multiplication factor equal to the ratio of WHO to

18

IHME envelopes The median country-year envelope ratio (WHOIHME) was 11 (interquartile

range 1-16)

Among the countries for which VR or mortality survey data could be used there were 1586

country-year data points 2000ndash2018 after removing 120 country-year data points with insufficient

data quality as estimated by WHO33 (Figure 4)

Reports of TB mortality are adjusted upwards to account for incomplete coverage (estimated deaths

with no cause documented) and ill-defined causes of death (ICD-9 B46 ICD-10 R00ndashR99)33 It is

assumed that the proportion of TB deaths among deaths not recorded by the VR system was the

same as the proportion of TB deaths in VR-recorded deaths For VR-recorded deaths with

ill-defined causes it is assumed that the proportion of deaths attributable to TB is the same as the

observed proportion in recorded deaths The adjusted number of TB deaths κa is obtained from the

VR report κ as follows

where v denotes coverage (ie the number of deaths with a documented cause divided by the total

number of estimated deaths) and g denotes the proportion of ill-defined causes The uncertainty

related to the adjustment was estimated as follows

The uncertainty calculation does not account for miscoding such as HIV deaths miscoded as deaths

due to TB except in South Africa

Missing data between existing adjusted data points are interpolated Trailing missing values are

predicted using a Kalman smoother or using the last observation carried forward or in the case of

leading missing values the next observation carried backwards

19

In 2018 58 of global TB mortality (excluding HIV) was directly measured from VR or survey data

(or imputed from survey or VR data from previous years) The remaining mortality was estimated

using the indirect methods described in the next section

Estimating TB mortality among HIV-negative people from estimates of case

fatality rates and TB incidence

In countries lacking mortality data of the necessary coverage and quality TB mortality is estimated

as the product of TB incidence and the case fatality rate (CFR) after disaggregation by case type as

shown in Table 4 following a literature review of CFRs by the TB Modelling and Analysis

Consortium (TB-MAC)

(5)

where M denotes mortality I incidence fu and ft denote CFRs untreated and treated respectively and

the superscript denotes HIV status T denotes the number of treated TB cases In countries where

the number of treated patients that are not notified (under-reporting) is known from an inventory

study the number of notified cases is adjusted upwards to estimate T- accounting for

under-reporting

Figure 5 shows a comparison of most recent direct mortality estimates and indirect estimates

obtained from the CFR approach for the same countries Of note countries with VR data tend to be

of a higher socio-economic status compared with countries with no VR data where the indirect

approach is used

Estimating TB mortality among HIV-positive people

TB mortality among HIV-positive is calculated using equation 5 exchanging superscripts - with +

The case fatality ratios were obtained in collaboration with the TB Modeling and Analysis

Consortium (TB-MAC) and are shown in Table 5 The disaggregation of incident TB into treated

and not treated cases is based on the numbers of notified cases adjusted for under-reporting

20

Direct measurements of HIV-associated TB mortality are urgently needed This is especially the case

for countries such as South Africa and Zimbabwe where national VR systems are already in place

In other countries more efforts are required to initiate the implementation of sample VR systems as

an interim measure

Disaggregation of TB mortality by age and sex

TB mortality is disaggregated by age and sex using the age- and sex-specific adjusted (for coverage

and ill-defined causes) number of deaths from VR data in countries with high-quality vital

registration systems in place (ie where these data have been used to estimate the TB mortality

envelope) For other countries adult mortality is disaggregated by age sex and HIV-infection status

by applying CFRs to disaggregated incidence estimates distinguishing CFR by anti-TB treatment

status and HIVART status (see Tables 4 and 5) TB mortality in children for these countries is also

estimated from TB incidence in children using a case-fatality based approach34 This approach

distinguishes case fatality children by age anti-TB treatment status and HIVART status

HIV-positive TB deaths in adults are distributed by age and sex proportional to age- and sex-specific

HIV prevalence from UNAIDS estimates in such a way as to maintain the estimated total number

of HIV-positive TB deaths

Estimating deaths averted

An estimate of the number of deaths averted is obtained by comparing a counterfactual where all

incident cases would be untreated using CFRs for untreated TB shown in Table 1 to a factual of

TB mortality as estimated using methods described above

21

7 Estimation of uncertainty There are many potential sources of uncertainty associated with estimates of TB incidence

prevalence and mortality as well as estimates of the burden of HIV-associated TB and MDR-TB

These include uncertainties in input data in parameter values in extrapolations used to impute

missing data and in the models used Uncertainty in population estimates is not accounted for

Notification data are of uneven quality Cases may be under-reported (for example missing quarterly

reports from remote administrative areas are not uncommon) misclassified (in particular

misclassification of recurrent cases in the category of new cases is common) or over-reported as a

result of duplicated entries in TB information systems or due to over-diagnosis The latter issues can

only be addressed efficiently in countries with case-based nationwide TB databases that include

patient identifiers Sudden changes in notifications over time are often the result of errors or

inconsistencies in reporting

Uncertainty bounds and ranges are defined as the 25th and 975th centiles of outcome distributions

The general approach to uncertainty analyses is to propagate errors in m real-valued random

variables X by approximating a function h(X) using second-order Taylor series expansion about its

moments3536 Using matrix notation the expected value E[h(X)] and variance of h(X) were

approximated as follows

where tr denotes the trace H(h) the Hessian matrix of partial second-order derivatives of h(X) with

respect to each Xi=1m the gradient matrix of partial first-order derivatives and the

joint covariance matrix of X

22

8 Conclusion

The measurement methods described here can be combined to assess tuberculosis incidence and

mortality to evaluate progress towards targets for tuberculosis control and the SDGs for TB

Alternative TB burden estimation methods have been developed by the Institute of Health Metrics

and Evaluation37 with generally consistent results at the global level compared with WHO but with

marked differences in specific countries Discrepancies in estimates from different agencies reflect

the questionable quality and completeness of the underlying data Further convergence in estimates

will result from improvements in measurements at country level National control programmes

should be able to measure the level and time trends in incidence through well-performing TB

surveillance with universal access to health In countries with incomplete routine surveillance

prevalence surveys of TB disease provide estimates of TB burden that do not heavily rely on expert

opinion The performance of TB surveillance should be assessed periodically10 and the level of

under-reporting should be measured9 and minimized Tuberculosis mortality will ideally be measured

by counting deaths in a comprehensive vital registration system33

WHOrsquos post-2015 global TB strategy known as the End TB Strategy38 has the goal of ending the

global TB epidemic with corresponding targets of a 90 reduction in TB deaths and an 80

reduction in the TB incidence rate by 2030 compared with 2015 Improved measurements through

substantial investments in health information systems TB surveillance and the broader SDG agenda

will provide a firmer basis for monitoring progress towards the End TB Strategy targets and ultimate

TB elimination

Acknowledgements

Ibrahim Abubakar Sandra Alba Elisabeth Allen Martien Borgdorff Jaap Broekmans Ken Castro

Frank Cobelens Ted Cohen Charlotte Colvin Sarah Cook-Scalise Liz Corbett Simon Cousens

Katherine Fielding Peter Godfrey-Faussett Yohhei Hamada Rein Houben Helen Jenkins Aviansh

23

Kanshar Li Liu Mary Mahy Valeacuterie Schwoebel Cherise Scott James Seddon Babis Sismanidis

Andrew Thomson Edine Tiemersma Hazim Timimi Theo Vos Emilia Vynnycky and Richard

White reviewed the described methods to derive TB incidence prevalence and mortality with

disaggregation by age and sex and provided specific recommendations to improve them

24

Annex 1 - Definitions

Incidence is defined as the number of new and recurrent (relapse) episodes of TB (all forms)

occurring in a given year Recurrent episodes are defined as a new episode of TB in people who have

had TB in the past and for whom there was bacteriological confirmation of cure andor

documentation that treatment was completed

Prevalence is defined as the number of TB cases (all forms) at a the middle of the year

Mortality from TB is defined as the number of deaths caused by TB in HIV-negative people

occurring in a given year according to the latest revision of the International classification of

diseases (ICD-10) TB deaths among HIV-positive people are classified as HIV deaths in ICD-10

For this reason estimates of deaths from TB in HIV-positive people are presented separately from

those in HIV-negative people

The case fatality rate is the risk of death from TB among people with active TB disease

The case notification rate refers to new and recurrent episodes of TB notified for a given year

Patients reported in the unknown history category are considered incident TB episodes (new or

recurrent)

Population estimates were obtained from the World Population Prospects which is produced by

the United Nations Population Division (UNPD httpesaunorgunpdwpp) The UNPD

estimates sometimes differ from those made by countries

25

Annex 2 - Relationship between HIV prevalence in new TB cases and HIV

prevalence in the general population

Let I and N denote incident cases and the total population respectively superscripts + and - denote

HIV status ϑ is the prevalence of HIV among new TB cases h is the prevalence of HIV in the

general population and ρ is the incidence rate ratio (HIV-positive over HIV-negative)

The TB incidence rate ratio ρ can be estimated by fitting the following linear model with a slope

constrained to 1

26

Annex 3 - Implementation steps

The methods described in the paper were implemented in the following steps

1 Reviewing available prevalence measurements from surveys adjusting for childhood TB

clinically diagnosed pulmonary and extra-pulmonary TB

2 Cleaning and adjusting raw mortality data from VR systems and mortality surveys followed

by imputation of missing values in countries with VR or survey data

3 Cleaning drug resistance survey data

4 Estimating overall TB incidence after review and cleaning of case notification data

5 Cleaning of measurements of HIV prevalence among TB patients followed by estimating

HIV-positive TB incidence and HIV-positive TB mortality

6 Estimating RR-TB and MDR-TB incidence

7 Estimating TB mortality in countries with no VR data and HIV-negative TB mortality

8 Estimating incidence and mortality disaggregated by age and sex and disaggregated by drug

resistance status

27

Annex 4 - Estimating the number of household contacts of a

bacteriologically confirmed pulmonary cases less than 5 years old

In low TB burden countries (113 high-income or upper middle-income countries with an estimated

incidence rate less than 100 per 100 000 population) the number of child household contacts

eligible for LTBI treatment is defined as the number of children under 5 years of age who are

household contacts of bacteriologically confirmed pulmonary TB cases and have LTBI defined as a

positive result to a standard tuberculin test or an IGRA test In high TB burden countries the

number eligible is defined as the number of child household contacts without active TB based on

the current WHO recommendations that do not require LTBI testing among child household

contacts lt5 years prior to the provision of preventive treatment in these countries12

The estimated number n of child household contacts eligible for LTBI treatment is

where b is the number of notified bacteriologically confirmed pulmonary TB c is the average

number of TB cases per household H is the average household size p is national proportion of

children lt5 years t is proportion of child household contacts with active TB and L is prevalence of

LTBI among child household contacts lt 5 years old In high TB burden countries L is set to 1

(testing for LTBI is not required) The following sources of uncertainty are accounted for

prevalence of LTBI variance in the count of TB cases per household and in the proportion of child

household contacts with active TB Uncertainty about United Nations Population Division (UNPD)

population size is not documented Errors were propagated using methods described in chapter 7

28

Parameters Values Sources

Number of notified bacteriologically confirmed pulmonary TB in 2015

Differ by country WHO global TB database

National proportion of children lt5 years of age in 2015

Differ by country 2015 Revision of World Population United Nations Population Division (httpsesaunorgunpdwpp)

National average household size Differ by country National censuses DHS statistical year books or official websites of the national statistical authorities

Prevalence of LTBI among child household contacts lt5years old in LBC

Constant across countries = 276 (192-380)

Systematic review of literature from LBC up to Dec 2015 (unpublished)

Average cluster size of active TB per household

Constant across countries =106 (95CI 104-108)

Systematic review of literature between Jan 2005 and Dec 2015 (unpublished)

Proportion of children lt 5 years old with active TB among those who had a household contact with TB cases

Constant across countries

=61 (95CI 10-163)

Source Dodd et al Lancet Glob Health 20143

1 World Health Organization Recommendations for Investigating Contacts of Persons with Infectious Tuberculosis in Low- and Middle-Income CountriesGeneva Switzerland WHO 2012

2 World Health Organization Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings Geneva Switzerland WHO 2011

3 Dodd PJ Gardiner E Coghlan R Seddon JA Burden of childhood tuberculosis in 22 high-burden countries a mathematical modelling study Lancet Glob Health 2014 2(8) e453-9

29

Tables

Table 1 Distribution of disease duration by case category

Case category Distribution of disease duration

(year)

Treated HIV-negative Uniform (02minus2)

Not treated HIV-negative Uniform (1minus4)

Treated HIV-positive Uniform(001minus1)

Not treated HIV-positive Uniform (001minus02)

Table 2 Incidence estimation based on UT

U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30

Table 3 Estimates of incidence derived from prevalence survey results based on two estimation

methods

Prevalence

(10-3)

Incidence - Method 1

(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)

Table 4 Distribution of CFRs by case category

CFR Sources

Not on TB treatment fu 043 (028-053) 3940

On TB treatment ft 003 (0-007) 41

31

Table 5 Distribution of CFR in HIV-positive individuals

ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142

lt 1 year off 062 (039-086) Data from review + assumptions

lt 1 year on 006 (001-013) Data from review + assumptions

ge 1 year off 049 (031-070) Assumptions

ge 1 year on 004 (000-010) Assumptions

32

Figures

Figure 1 Main method to estimate TB incidence In the first method case notification data are combined with expert opinion about case detection gaps (under-reporting and under-diagnosis) and trends are estimated using either mortality data repeat surveys of the annual risk of infection or exponential interpolation using estimates of case detection gaps for three years For all high-income countries except the Netherlands and the United Kingdom and selected countries of other income groups notifications are adjusted by a standard amount or measures of under-reporting from inventory studies to account for case detection gaps

33

Figure 2 HIV prevalence ratio (prevalence survey notified TB cases)

34

Figure 3 Main methods to estimate TB mortality in HIV-negative people

Figure 4 VR data quality

35

Figure 5 Comparison of VR mortality (HIV-negative) horizontal axis (log scale) and mortality

predicted as the product of incidence and CFR vertical axis (log scale) Horizontal and vertical

segments indicate uncertainty intervals The dashed red line shows equality The blue line and

associated grey banner show the least-squared best fit to the data

References

1 Dye C Bassili A Bierrenbach AL et al Measuring tuberculosis burden trends and the impact of control programmes Lancet Infect Dis 2008 8 233ndash43

2 Styblo K Styblo K The Relationship between the risk of tuberculous infection and the risk of developing infectious tuberculosis Bulletin of the International Union against Tuberculosis and Lung Diseases 1985 117ndash9

3 Van leth F Prevalence of tuberculous infection and incidence of tuberculosis a re-assessment of the Styblo rule Bull World Health Organ 2008 86 20ndash6

36

4 Dinnes J Deeks J Kunst H et al A systematic review of rapid diagnostic tests for the detection of tuberculosis infection Health Technol Assess 2007 11 1ndash196

5 Eilers PHC Borgdorff MW Modeling and correction of digit preference in tuberculin surveys Int J Tuberc Lung Dis 2004 8 232ndash9

6 Rieder HL Methodological issues in the estimation of the tuberculosis problem from tuberculin surveys Tuber Lung Dis 1995 76 114ndash21

7 Sudre P ten Dam G Kochi A Tuberculosis a global overview of the situation today Bull World Health Organ 1992 70 149ndash59

8 Dye C Scheele S Dolin P Pathania V Raviglione MC Others Global burden of tuberculosis estimated incidence prevalence and mortality by country JAMA 1999 282 677ndash86

9 WHO Assessing tuberculosis under-reporting through inventory studies World Health Organization 2012

10 WHO Standards and Benchmarks for tuberculosis surveillance and vital registration systems WHO 2014 httpwwwwhointtbpublicationsstandardsandbenchmarks

11 WHO Improving estimation of TB disease burden via systematic assessment of surveillance data httpwwwwhointtbadvisory_bodiesimpact_measurement_taskforcemeetingsimproving_estimatesen

12 Renyi A Probability Theory New York Dover Publications Inc 2007

13 Viechtbauer W Conducting Meta-Analyses in R with the metafor Package Journal of Statistical Software 2010 36 1ndash48

14 Bassili A Grant AD El-Mohgazy E et al Estimating tuberculosis case detection rate in resource-limited countries a capture-recapture study in Egypt Int J Tuberc Lung Dis 2010 14 727ndash32

15 Huseynova S Hashim DS Tbena MR et al Estimating tuberculosis burden and reporting in resource-limited countries a capture-recapture study in Iraq Int J Tuberc Lung Dis 2013 17 462ndash7

16 van HEST NAH Smit F Baars HWM et al Completeness of notification of tuberculosis in The Netherlands how reliable is record-linkage and capture-recapture analysis Epidemiol Infect 2007 135 1021ndash9

17 Anderson L Moore J Pedrazzoli D et al Tuberculosis in the UK 2010

18 Bassili A Al-Hammadi A Al-Absi A et al Estimating the tuberculosis burden in resource-limited countries a capture-recapture study in Yemen Int J Tuberc Lung Dis 2013 17

37

456ndash61

19 Al-Absi A Bassili A Abdul Bary H et al The decline of tuberculosis in Yemen evaluation based on two nationwide tuberculin surveys Int J Tuberc Lung Dis 2009 13 1100ndash5

20 WHO Definitions and reporting framework for tuberculosis 2013 revision WHO WHO 2013 httpwwwwhointtbpublicationsdefinitions

21 Van Hest NAH Story A Grant AD Antoine D Crofts JP Watson JM Record-linkage and capturendashrecapture analysis to estimate the incidence and completeness of reporting of tuberculosis in England 1999ndash2002 Epidemiol Infect 2008 136 1606

22 Lestari T Probandari A Hurtig A-K Utarini A High caseload of childhood tuberculosis in hospitals on Java Island Indonesia a cross sectional study BMC Public Health 2011 11 784

23 Coghlan R Gardiner E Amanullah F et al Understanding Market Size and Reporting Gaps for Paediatric TB in Indonesia Nigeria and Pakistan Supporting Improved Treatment of Childhood TB in the Advent of New Medicines PLoS One 2015 10 e0138323

24 WHO WHO Global Task Force on TB Impact Measurement - Sub-group on strengthening surveillance 2014 published online Nov 6 httpwwwwhointtbadvisory_bodiesimpact_measurement_taskforcemeetingssep14indonesia_inventorystudyworkshopen (accessed Oct 15 2015)

25 Horton KC MacPherson P Houben RMGJ White RG Corbett EL Sex Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries A Systematic Review and Meta-analysis PLoS Med 2016 13 e1002119

26 Dodd PJ Gardiner E Coghlan R Seddon JA Burden of childhood tuberculosis in 22 high-burden countries a mathematical modelling study The Lancet Global Health 2014 2 e453ndash9

27 World Health Organization Who Estimates of the Global Burden of Foodborne Diseases Foodborne Disease Burden Epidemiology Reference Group 2007-2015 2016

28 Muumlller B Duumlrr S Alonso S et al ZoonoticMycobacterium bovisndashinduced Tuberculosis in Humans Emerging Infectious Diseases 2013 19 899ndash908

29 WHO WHO treatment guidelines for drug resistant tuberculosis - 2016 Update WHO 2016 httpappswhointirisbitstream1066525012519789241549639-engpdfua=1

30 Mortality and causes of death in South Africa 2010 Findings from death notification httpwwwstatssagovzapublicationsp03093p030932010pdf (accessed Sept 2016)

31 Glaziou P van der Werf MJ Onozaki I et al Tuberculosis prevalence surveys rationale and cost Int J Tuberc Lung Dis 2008 12 1003ndash8

38

32 WHO Tuberculosis Prevalence Surveys A Handbook World Health Organization 2011

33 Mathers CD Fat DM Inoue M Rao C Lopez AD Counting the dead and what they died from an assessment of the global status of cause of death data Bull World Health Organ 2005 83 171ndash7

34 Dodd PJ Yuen CM Sismanidis C Seddon JA Jenkins HE The global burden of tuberculosis mortality in children a mathematical modelling study Lancet Glob Health 2017 5 e898ndash906

35 Ku HH Notes on the use of propagation of error formulas Journal of Research of the National Bureau of Standards Section C Engineering and Instrumentation 1966 70C 263

36 Lab AS An Introduction To Error Propagation Derivation Meaning and Examples of Equation C_Y=F_X C_X F^X_T Swiss Federal Institute of Technology Lausanne 1998 httpwwwnadakthse~kai-apapersarrasTR-9801-R3pdf

37 Murray CJL Ortblad KF Guinovart C et al Global regional and national incidence and mortality for HIV tuberculosis and malaria during 1990ndash2013 a systematic analysis for the Global Burden of Disease Study 2013 Lancet 2014 6736 1ndash66

38 Uplekar M Weil D Lonnroth K et al WHOrsquos new end TB strategy Lancet 2015 385 1799ndash801

39 Corbett EL Watt CJ Walker N et al The growing burden of tuberculosis global trends and interactions with the HIV epidemic Arch Intern Med 2003 163 1009ndash21

40 Tiemersma EW van der Werf MJ Borgdorff MW Williams BG Nagelkerke NJD Natural history of tuberculosis duration and fatality of untreated pulmonary tuberculosis in HIV negative patients a systematic review PLoS One 2011 6 e17601

41 Straetemans M Glaziou P Bierrenbach AL Sismanidis C van der Werf MJ Assessing tuberculosis case fatality ratio a meta-analysis PLoS One 2011 6 e20755

42 Mukadi YD Maher D Harries A Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa AIDS 2001 15 143ndash52

39

Abstract

This paper describes methodological details used by WHO in 2019 to estimate TB incidence and

mortality Incidence and mortality are disaggregated by HIV status age and sex Methods to derive

MDR-TB burden indicators are detailed Four main methods are used to derive incidence (i) results

from TB prevalence surveys (24 countries 60 of global incidence) (ii) notifications in high-income

countries adjusted by a standard factor to account for under-reporting and underdiagnosis (142

countries 6 of global incidence) and (iii) national inventory studies (7 countries 18 of global

incidence) (iv) case notification data combined with expert opinion about case detection gaps (43

countries representing 16 of global incidence in 2018) Mortality was obtained from national vital

registration systems of mortality surveys in 123 countries (55 of global HIV-negative TB

mortality) and among 20 of them based on estimates published by the Institute of Health Metrics

and Evaluation In other countries mortality was derived indirectly from incidence and case fatality

ratio

1


























2




3 Incidence


















incidence10





3





























4





















notifications



5

(1)







follows



TB cases



incidence








6













(3)






recall biases






7








where







8






















(4)

9




























10






















was 19 (17 ndash 22) in 2015



11












age and sex









surveillance data








12

























13

























14

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39


























2




3 Incidence


















incidence10





3





























4





















notifications



5

(1)







follows



TB cases



incidence








6













(3)






recall biases






7








where







8






















(4)

9




























10






















was 19 (17 ndash 22) in 2015



11












age and sex









surveillance data








12

























13

























14

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39




3 Incidence


















incidence10





3





























4





















notifications



5

(1)







follows



TB cases



incidence








6













(3)






recall biases






7








where







8






















(4)

9




























10






















was 19 (17 ndash 22) in 2015



11












age and sex









surveillance data








12

























13

























14

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39





























4





















notifications



5

(1)







follows



TB cases



incidence








6













(3)






recall biases






7








where







8






















(4)

9




























10






















was 19 (17 ndash 22) in 2015



11












age and sex









surveillance data








12

























13

























14

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39





















notifications



5

(1)







follows



TB cases



incidence








6













(3)






recall biases






7








where







8






















(4)

9




























10






















was 19 (17 ndash 22) in 2015



11












age and sex









surveillance data








12

























13

























14

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39

(1)







follows



TB cases



incidence








6













(3)






recall biases






7








where







8






















(4)

9




























10






















was 19 (17 ndash 22) in 2015



11












age and sex









surveillance data








12

























13

























14

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39













(3)






recall biases






7








where







8






















(4)

9




























10






















was 19 (17 ndash 22) in 2015



11












age and sex









surveillance data








12

























13

























14

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39








where







8






















(4)

9




























10






















was 19 (17 ndash 22) in 2015



11












age and sex









surveillance data








12

























13

























14

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39






















(4)

9




























10






















was 19 (17 ndash 22) in 2015



11












age and sex









surveillance data








12

























13

























14

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39




























10






















was 19 (17 ndash 22) in 2015



11












age and sex









surveillance data








12

























13

























14

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39






















was 19 (17 ndash 22) in 2015



11












age and sex









surveillance data








12

























13

























14

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39












age and sex









surveillance data








12

























13

























14

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39

























13

























14

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39

























14

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39

















MDRRR-TB incidence


with MDRRR-TB





15




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39




most recent years

MDRRR TB mortality








formula

Where









16



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39



global estimate















17













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39













HIV-negative people


CFR









18


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39


range 1-16)



















19









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39









Consortium (TB-MAC)

(5)





under-reporting




approach is used






20




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39




an interim measure

















21




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39




















22

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39

8 Conclusion



















TB elimination

Acknowledgements




23





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39





24















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39















recurrent)




25







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39







constrained to 1

26














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39














resistance status

27




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39




















28















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39















=61 (95CI 10-163)





29

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39

Tables



(year)






U (n)

T (n)

Prevalence (10-3)

Duration (year)

Incidence (10-3y-1)

Cambodia 2002 260 42 12 (10-15) 29 (19-4) 4 (25-58)

Cambodia 2011 205 80 83 (71-98) 12 (08-16) 67 (45-93)

Myanmar 2009 300 79 61 (5-75) 18 (11-16) 33 (2-48)

Thailand 2012 136 60 25 (19-35) 11 (05-16) 23 (1-35)

30


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39


methods

Prevalence

(10-3)


(10-3y -1)


(10-3y -1)

Cambodia 2002 12 (10-15) 4 (25-58) 22 (15-29)

Cambodia 2011 83 (71-98) 67 (45-93) 38 (22-58)

Myanmar 2009 61 (5-75) 33 (2-48) 35 (2-51)

Thailand 2012 25 (19-35) 23 (1-35) 11 (07-16)


CFR Sources



31


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39


ART TB

treatment

CFR Sources

off off 078 (065-094) 39

off on 009 (003-015) 4142





32

Figures


33


34



35





References




36
















37

456ndash61














38












39

Figures


33


34



35





References




36
















37

456ndash61














38












39


34



35





References




36
















37

456ndash61














38












39



35





References




36
















37

456ndash61














38












39





References




36
















37

456ndash61














38












39
















37

456ndash61














38












39

456ndash61














38












39












39

Methods used by WHO to estimate the global burden of TB ...

Documents